VANCOUVER, CANADA – September 6, 2018 – Evasc Neurovascular Enterprises ULC announced today that it has signed a distribution agreement with Logsa Endomedical for Spain and Portugal.
“Extending into Spain and Portugal with Logsa Endomedical continues our strategy of building a strong foundation of Distributors in Europe with leaders in the neurovascular field. We look forward to bringing the eCLIPs device to the region and improving patient outcomes.” said Dr. Donald Ricci, President and Chief Executive Officer of Evasc.
Juan Antonio Delgado, Chief Executive Officer of Logsa Endomedical stated “We are impressed with the eCLIPs device and its efficacy in treating cerebral aneurysms at bifurcations. We see a strong need for this type of novel device in the market.”
In development since 2008, eCLIPs is a patented endovascular device designed to treat 95% of cerebral aneurysm cases, and is currently targeted for use in challenging wide-neck bifurcations. eCLIPs combines the best properties of stents and diverters, and can be used for coil retention and to enhance flow disruption. eCLIPs avoids dangerous entry into the dynamic, fragile environment of the aneurysm sac, while protecting and providing a platform for endothelial growth across the bifurcation neck. To date, eCLIPs has been used to treat cerebral aneurysms in over 50 patients in Canada and 9 European countries.
Evasc Neurovascular is a privately held medical device company focused on the development of disruptive endovascular treatments for cerebral aneurysms. Evasc received approval for use of eCLIPs in Canada under the Special Access Program in 2013, and received CE mark approval in 2015. Evasc is headquartered in Vancouver, Canada.
Evasc Neurovascular is on the web at www.evasc.com.
For more information, contact Scott Wilson at +1 (604) 742-3811, email@example.com.